Rocket Lab jumps 7% on analyst upgrade, Mynaric deal momentum boosts sentiment

RKLBRKLB

Rocket Lab shares rose after a fresh analyst upgrade to Buy/Outperform with an $85 price target highlighted improving risk-reward and accelerating defense and space-systems momentum. The move also extends recent momentum tied to German regulatory approval for Rocket Lab’s planned acquisition of Mynaric, expected to close in April 2026.

1. What’s moving the stock

Rocket Lab (RKLB) is trading sharply higher today as investors react to a bullish analyst call that upgraded the stock to a Buy/Outperform-equivalent rating and reiterated an $85 price target, framing the setup as a more attractive risk-to-reward opportunity at current levels. The upgrade is being treated as a near-term catalyst, pulling in momentum buyers after a choppy stretch for high-growth aerospace names. (tipranks.com)

2. Deal-driven tailwinds remain in focus

Today’s pop is also building on recently improved M&A clarity after Rocket Lab said it received German regulatory approval to acquire Mynaric, a laser optical communications terminal supplier, positioning the combined company for deeper vertical integration across spacecraft communications. Rocket Lab has said the transaction is expected to close in April 2026, keeping attention on a closing announcement and integration details as the next headline risk/reward. (rocketlabcorp.com)

3. Why the tape is rewarding the story now

With the stock already sensitive to defense and space-systems growth narratives, incremental “de-risking” signals—like regulatory clearance on a strategic acquisition—can have an outsized effect on positioning and short-term price action. Traders are effectively repricing the probability of Rocket Lab expanding its space-systems platform into higher-value communications payloads while maintaining momentum in its government-facing portfolio. (rocketlabcorp.com)

4. What to watch next

Key near-term watch items are (1) an explicit transaction close timeline and any purchase-price/financing updates for Mynaric, (2) early integration milestones and customer cross-sell commentary, and (3) the next scheduled financial update (widely tracked as early May 2026 estimates) for updated guidance and execution checkpoints. If the deal closes on schedule, focus is likely to shift from “approval” headlines to whether the acquisition translates into margin, backlog conversion, and program wins. (benzinga.com)